RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65.

9102Background: Tislelizumab is a humanized, monoclonal antibody with high affinity and specificity for the programmed cell death protein 1 (PD-1). It has demonstrated antitumor activity in advance...